Project description
Profiling cancer cell proteins to better understand cell communication in tumours
Cancer is a large and complex group of diseases characterised by abnormal and uncontrolled growth of some cells in the body. The cancerous cells can invade adjoining tissues or travel to other parts of the body and metastasis is a major cause of death from cancer. Understanding tumour dynamics is critical for the development of novel therapeutic approaches. The EU-funded ProACCT project will use high-tech methods to assay thousands of proteins from single cells and groups of cells from in vivo samples as well as map primary tumours and metastases at high spatial resolution. Outcomes will aid in targeting treatment-resistant metastatic cell populations in the context of personalised medicine.
Objective
Cancer is an enormous biomedical challenge, in part due to the complexity of cancer cell dynamics. The combination of intrinsic genetic alterations and cues from the tumour microenvironment impact the cancer phenotype and create heterogeneous tumours that evolve in space and time. Cancer cells develop distinct phenotypes in diverse tumour regions and different metastatic locations. In addition, cancer progression, metastatic dissemination, and development of therapeutic resistance affect cellular interactions over time. Therefore, understanding tumour dynamics is critical for the development of novel therapeutic approaches.
Although tumour heterogeneity has been thoroughly investigated at the genomic and transcriptomic levels, limited studies have investigated heterogeneity at the proteomic level. Changes in protein expression are central determinants of cancer phenotypes; developing a detailed understanding of proteome dynamics would be an enormous scientific advancement in the cancer field. However, technological challenges, and specifically, the challenge of analysing single cells and small groups of cells, have delayed progress along these lines. Here, I propose to combine my cutting-edge clinical proteomic expertise and extensive experience in cancer biology to study the spatial and temporal heterogeneity of cancer at the proteomic level.
We will push the boundaries of the technology towards assaying thousands of proteins from single cells and small groups of cells from in-vivo samples. We will combine microfluidic probe technology to map primary tumors and metastases at high spatial resolution, and study mouse models of melanoma and breast cancer to follow temporal changes in metastatic growth and treatment response. This breakthrough in proteomic analysis of cancer dynamics will provide the basis for targeting treatment-resistant metastatic cell populations towards advanced personalized treatment.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteinsproteomics
- medical and health sciencesclinical medicineoncologyskin cancermelanoma
You need to log in or register to use this function
Programme(s)
- HORIZON.1.1 - European Research Council (ERC) Main Programme
Funding Scheme
HORIZON-ERC - HORIZON ERC GrantsHost institution
7610001 Rehovot
Israel